Skip to main content

Table 1 Schedule of assessments

From: A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

  1. *It is planned that week 104 data will be collected from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) or UK Bronchiectasis Registry (BRONCH-UK). If this is not possible, the participant will be asked to visit the research site for the data to be collected. BE, bronchiectasis; QoL-B, Quality of Life - Bronchiectasis; SGRQ, Saint George’s Respiratory Questionnaire; EQ-5D-5L, EuroQoL five dimension five level questionnaire
Back to article page

Trials

ISSN: 1745-6215